Ernexa Therapeutics Inc. Retained Earnings
Ernexa Therapeutics Inc. (ERNA) had Retained Earnings of -$255.16 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$255.16M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$251.14M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$245.64M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$244.13M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$255.16M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$251.14M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | -$245.64M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$244.13M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | -$242.88M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$239.74M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | -$231.54M 10-K · filed 2026-03-13 | |
| 2024-09-30 | -$225.77M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$199.16M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$193.63M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$186.98M 10-K · filed 2025-03-12 | |
| 2023-09-30 | -$180.82M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$175.23M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | -$170.71M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$165.30M 10-K · filed 2024-03-14 | |
| 2022-09-30 | -$160.80M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$153.48M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$150.08M 10-Q · filed 2022-07-01 | |
| 2021-12-31 | -$140.70M 10-K · filed 2023-03-20 | -$159.70M 10-K · filed 2022-04-15 |
| 2021-09-30 | -$132.74M 10-K/A · filed 2022-07-01 | -$151.23M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$46.76M 10-K/A · filed 2022-07-01 | -$65.18M 10-Q · filed 2021-08-13 |
| 2021-03-31 | -$36.66M 10-K/A · filed 2022-07-01 | -$55.08M 10-Q · filed 2021-05-17 |
| 2020-12-31 | -$18.14M 10-K/A · filed 2022-07-01 | -$135.89M 10-K · filed 2021-03-11 |
| 2020-09-30 | -$136.19M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | -$134.71M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | -$132.68M 10-Q · filed 2020-05-20 | |
| 2019-12-31 | -$131.46M 10-K · filed 2021-03-11 | |
| 2019-09-30 | -$130.16M 10-Q · filed 2019-11-01 | |
| 2019-06-30 | -$129.81M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | -$129.71M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | -$129.39M 10-K · filed 2020-03-19 | |
| 2018-09-30 | -$129.44M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | -$129.66M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | -$129.53M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | -$129.12M 10-K · filed 2019-03-22 | |
| 2017-09-30 | -$128.47M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | -$128.29M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | -$128.12M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | -$128.03M 10-K · filed 2018-03-09 | |
| 2016-09-30 | -$127.56M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | -$126.99M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$126.13M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | -$125.09M 10-K · filed 2017-03-09 | |
| 2015-09-30 | -$124.09M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | -$122.74M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | -$120.11M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | -$117.84M 10-K · filed 2016-03-15 | |
| 2014-09-30 | -$116.12M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | -$114.80M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | -$113.45M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | -$112.80M 10-K · filed 2015-03-27 | |
| 2013-09-30 | -$112.44M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | -$112.21M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | -$112.10M 10-Q · filed 2013-05-13 | |
| 2012-12-31 | -$111.73M 10-K · filed 2014-03-31 | |
| 2012-09-30 | -$112.35M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | -$112.41M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | -$111.76M 10-Q · filed 2012-05-11 | |
| 2011-12-31 | -$110.72M 10-K · filed 2013-03-29 | |
| 2011-09-30 | -$109.67M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | -$108.83M 10-Q · filed 2011-08-12 | |
| 2010-12-31 | -$107.28M 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |